Historical record - last NADAC effective date: 2/21/2018
Product Information
CARBIDOPA-LEVO ER 25-100 TAB is a generic product labeled by Accord Healthcare Inc., priced at $0.3233 per EA under NDC 16729007817. Its NADAC has been published 219 times since Dec 18, 2013.
FDA first approved this application on Feb 8, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25; 100 mg/1; mg/1
Manufacturer
Accord Healthcare Inc.NDC
16729007817
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
2/21/2018
Active Ingredients
CARBIDOPA; LEVODOPAApproval Type
Generic (ANDA)
FDA Application
ANDA202323FDA Approved
2/8/2013
TE Code
AB
On Market Since
6/13/2013
Pharmacological Classes
Price Statistics
The NADAC for CARBIDOPA-LEVO ER 25-100 TAB has been published 219 times since Dec 18, 2013, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3233 per EA |
|---|---|
| All-time high | $0.3892 (May 13, 2015) |
| All-time low | $0.2414 (Mar 22, 2017) |
| Median price | $0.2886 |
| Average price | $0.2920 |
| Largest weekly change | +35.9% (Jan 17, 2018) |
| Weeks tracked | 219 |
| Tracking since | Dec 18, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
-0.3%
Last surveyed Feb 21, 2018 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 9 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 76% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of CARBIDOPA-LEVO ER 25-100 TAB?
The current National Average Drug Acquisition Cost (NADAC) for CARBIDOPA-LEVO ER 25-100 TAB, manufactured by Accord Healthcare Inc., is $0.3233 per EA (NDC 16729007817), effective Feb 21, 2018.
How has the price of CARBIDOPA-LEVO ER 25-100 TAB changed over time?
Over the history we have for it, the NADAC for CARBIDOPA-LEVO ER 25-100 TAB has held within roughly two percent of its current level. It has been tracked across 219 weekly CMS publications since Dec 18, 2013.
What are the highest and lowest recorded NADAC prices for CARBIDOPA-LEVO ER 25-100 TAB?
Since Dec 18, 2013, the NADAC for CARBIDOPA-LEVO ER 25-100 TAB has ranged from a low of $0.2414 (Mar 22, 2017) to a high of $0.3892 (May 13, 2015), with a median of $0.2886 per EA.
Are there cheaper alternatives to CARBIDOPA-LEVO ER 25-100 TAB?
Yes. 9 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CARBIDOPA-LEVODOPA 25-100 TAB, is $0.0766 per EA — about 76% below CARBIDOPA-LEVO ER 25-100 TAB.
Who manufactures CARBIDOPA-LEVO ER 25-100 TAB?
CARBIDOPA-LEVO ER 25-100 TAB (NDC 16729007817) is labeled by Accord Healthcare Inc., and CMS classifies it as a generic product.